A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

Phase 1

Completed

• Conditions: HIV Infections

• Registration Number: NCT00303576
• Lead Sponsor: International Partnership for Microbicides, Inc.

Brief Summary

Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2006-03-15
• Study First Submitted QC: 2006-03-15
• Study First Posted: 2006-03-17
• Status Verified: 2006-07
• Study Completion: 2006-07
• Last Update Submitted: 2006-07-28
• Last Update Posted: 2006-07-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 112

Inclusion Criteria

• HIV-negative
• Willing to participate and sign an informed consent
• Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group.
• Willing to use two forms of contraception during the study.
• Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study.
• Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses.
• Willing to abstain from using any vaginal product (other than the study product or placebo).
• Willing to be sexually abstinent from randomization until completion of Day 7 evaluations.

Exclusion Criteria

• Currently pregnant or breast-feeding.
• Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.
• Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.
• Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.
• Symptomatic bacterial vaginosis and unwilling to undergo treatment.
• Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Local and systemic safety and tolerability.

Trial Locations

Locations (4)

Projet Ubuzima; 🇷🇼 Kigali, Rwanda

Kilimanjaro Reproductive Health Program; 🇹🇿 Moshi, Tanzania

Reproductive Health Research Unit - Sheshisani IPM Clinic; 🇿🇦 Yeoville, Johannesburg, South Africa

Farmovs-Parexel; 🇿🇦 Bloemfontein, South Africa